On March 12, the State Food and Drug Administration issued a notice approving the change of covid-19 antigen product self-test application of Nanjing Nanjing Vazyme Biotech Co.Ltd(688105) , Beijing jinwofu, Shenzhen Huada Yinyuan, Guangzhou Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing huaketai biology.
Since then, five covid-19 antigen self-test products have been officially launched.
On March 11, the official website of the National Health Commission issued the notice on printing and distributing the application scheme for covid-19 virus antigen detection (Trial) (hereinafter referred to as the application scheme), And the supporting basic operation process of covid-19 virus antigen detection in primary medical and health institutions (hereinafter referred to as the operation process of primary medical institutions) and the basic requirements and process of covid-19 virus antigen self-test.
The application plan points out that antigen detection is added as a supplement to nucleic acid detection. Community residents who need self-test can purchase antigen test reagents for self-test through retail pharmacies, online sales platforms and other channels. This means that the covid-19 antigen rapid test, which is popular all over the world, will be officially allowed to be put into use in China and provide a key basis for home testing.
Zhongtai Securities Co.Ltd(600918) research report points out that at present, the ex factory unit price of covid-19 antigen self-test kit in China is about US $1-1.50. With reference to the overseas distribution policy, although the distribution frequency of overseas covid-19 antigen self-test kit varies significantly, ranging from 2-10 times per capita, with reference to the overseas policy, it is assumed to be twice a month according to the lowest frequency, It is estimated that the market scale of covid-19 antigen self-test kit in China is expected to reach 17.7-26.6 billion yuan per month. Taking into account the purchase at their own expense by residents and enterprises, it is expected that the purchase demand of covid-19 antigen detection products is expected to further increase. According to this calculation, the market scale in one year is expected to exceed 100 billion yuan.
In fact, on March 11, there was a reaction in the secondary market. The stock prices of listed companies related to covid-19 testing rose sharply. The stock prices of listed companies providing rapid testing products such as Shanghai Labway Clinical Laboratory Co.Ltd(301060) , Kefu medicine, Wanfu medicine, Andon Health Co.Ltd(002432) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) , etc. rose by more than 10%. Although Andon Health Co.Ltd(002432) , Beijing Hotgen Biotech Co.Ltd(688068) , Zhejiang Orient Gene Biotech Co.Ltd(688298) and others later announced that there are no covid-19 antigen testing products listed in China, the testing market pattern will enter a new round of reshuffle, which is irreversible.
